DDB1 and CUL4 associated factor 13 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored DCAF13P2 profile across patient tissues and cancer cell-line models. DCAF13P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, DCAF13P2 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, DCAF13P2 RNA expression shows 8,783 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, STAD, and TGCT as cancer lineages where DCAF13P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF13P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF13P2 survival associations across molecular data types. DCAF13P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF13P2 RNA expression–survival associations across cancer types. High DCAF13P2 expression shows unfavorable associations in OV, KIRC, KICH and SKCM, but favorable associations in UVM and BLCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify OV as the clearest survival context for DCAF13P2 RNA expression.
This table summarizes DCAF13P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for DCAF13P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF13P2 shows higher tumor expression in STAD. The STAD box plot shows higher DCAF13P2 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .030).
This table shows molecular features associated with DCAF13P2 in patient tissues and cancer cell lines. In patient samples, DCAF13P2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
